Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China National MedicinesSHSE:600511 -0.04%90 Debt-to-EBITDA is 0.28 as of Jun. 2026, which is 8% above its 10-year median of 0.26. GuruFocus rates SHSE:600511 with a GF Score™ of 90/100 and a GF Value™ of ¥32.09 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 91 Medical Distribution companies, China National Medicines ranks better than 86.81% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for China National Medicines's Debt-to-EBITDA or its related term are showing as below:
SHSE:600511'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.17 Med: 0.26 Max: 0.62
Current: 0.24
During the past 13 years, the highest Debt-to-EBITDA Ratio of China National Medicines was 0.62. The lowest was 0.17. And the median was 0.26.
SHSE:600511's Debt-to-EBITDA is ranked better than 86.81% of 91
companies
in the Medical Distribution industry
Industry Median: 2.32
vs SHSE:600511: 0.24
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
China National Medicines Debt-to-EBITDA Related Terms
China National Medicines Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600511 vs MCK, COR, CAH: Debt-to-EBITDA Comparison
For the Medical Distribution subindustry, China National Medicines's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China National Medicines Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, China National Medicines's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where China National Medicines's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
China National Medicines (SHSE:600511) has a Debt-to-EBITDA of 0.28 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on China National Medicines. This is near median its historical median of 0.26. Over the past decade, China National Medicines' Debt-to-EBITDA has ranged from 0.17 to 0.62. According to the industry distribution chart, China National Medicines ranks #12 out of 91 companies in the Medical Distribution industry, placing it in the top 13.2%.
Is China National Medicines' Debt-to-EBITDA too high?
China National Medicines' current Debt-to-EBITDA of 0.28 is near median its 10-year median of 0.26. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 0.62. The Medical Distribution industry median Debt-to-EBITDA is 2.32. China National Medicines' value of 0.28 is 87.9% below this industry median. Based on the distribution chart, China National Medicines ranks #12 out of 91 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, China National Medicines has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China National Medicines' Debt-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, China National Medicines ranks #12 out of 91 companies for Debt-to-EBITDA. This places China National Medicines in the top 13% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.32. China National Medicines' value of 0.28 is 87.9% below this benchmark. Historically, China National Medicines' own Debt-to-EBITDA has ranged from 0.17 to 0.62 over the past decade. While the company's 10-year median is 0.26 vs. the industry median of 2.32, China National Medicines has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.32, based on 91 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China National Medicines's current Debt-to-EBITDA of 0.28 is 87.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on China National Medicines. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China National Medicines's current Debt-to-EBITDA is 0.28, which is near median its own 10-year median of 0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China National Medicines stock overvalued right now?
Based on GuruFocus' analysis, China National Medicines (SHSE:600511) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥32.09, compared to a current price of ¥26.77 — trading 16.6% below its estimated fair value. The current Debt-to-EBITDA is 0.28, which is near median its 10-year median of 0.26 and 87.9% below the Medical Distribution industry median of 2.32. China National Medicines' overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For China National Medicines (SHSE:600511), the current Debt-to-EBITDA is 0.28 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China National Medicines (SHSE:600511) Overvalued in 2026?
Based on GuruFocus' analysis, China National Medicines stock appears to be undervalued.
The current stock price of ¥26.77 is trading 16.6% below its estimated GF Value™ of ¥32.09.
GuruFocus considers China National Medicines to be Modestly Undervalued.
Key valuation signals for SHSE:600511:
Debt-to-EBITDA: 0.28 (near median its 10-year median of 0.26)
GF Value™: ¥32.09 vs. price of ¥26.77 (16.6% below fair value)
Industry Position: 87.9% below the Medical Distribution median (#12 of 91)
No single metric tells the full story. See the SHSE:600511 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China National Medicines Corp Ltd focuses on producing special drugs and high-end prescription drugs. Its main goal is to provide customers with professional medical services. The company conducts its operations through two primary segments. The Commercial segment is mainly engaged in the sale of pharmaceuticals. The Others segment focuses on pharmaceutical manufacturing and logistics operations.
90GF Score
Get the complete analysis for SHSE:600511
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600511 has been successfully added to your 
